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Abstract
Background: The CRISPR/Cas9 system is increasingly used for gene inactivation in mouse zygotes, but homology-
directed mutagenesis and use of inbred embryos are less established. In particular, Rosa26 knock-in alleles for the
insertion of transgenes in a genomic ‘safe harbor’ site, have not been produced. Here we applied CRISPR/Cas9 for
the knock-in of 8–11 kb inserts into Rosa26 of C57BL/6 zygotes.
Results: We found that 10–20 % of live pups derived from microinjected zygotes were founder mutants, without
apparent off-target effects, and up to 50 % knock-in embryos were recovered upon coinjection of Cas9 mRNA and
protein. Using this approach, we established a new mouse line for the Cre/loxP-dependent expression of Cas9.
Conclusions: Altogether, our protocols and resources support the fast and direct generation of new Rosa26 knock-in
alleles and of Cas9-mediated in vivo gene editing in the widely used C57BL/6 inbred strain.
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Background
The Rosa26 locus on chromosome 6 is frequently used
for the integration of transgene constructs to achieve
ubiquitous or conditional gene expression in mice. The
Rosa26 transcript is spliced into three exons and ubiqui-
tously expressed in all cell types and developmental
stages, but not translated to a protein [1]. The locus was
first identified by the integration of the Rosaβ-geo (reverse
orientation splice acceptor βGal) gene trap vector in pool
#26 of transduced embryonic stem (ES) cells [2]. This
integration site, residing at the XbaI site within the first in-
tron of Rosa26, has been used for ES-based gene targeting
from its discovery on. A Rosa26 targeting vector is extend-
ing 1 kb upstream and 4 kb downstream from the integra-
tion site within the first intron, flanking transgene inserts
[3]. In the classical gene targeting procedure, targeted ES
cell clones are injected into blastocysts to obtain germline
chimeric mice and the transmission of targeted alleles to
their offspring. This approach requires laborious handling
of ES cell cultures and waiting times of 9–12 months until
identification of positive F1 pups [4]. Nevertheless, the
Rosa26 locus is frequently targeted via ES cells for insert-
ing single transgene copies in a standardized configuration
into the mouse genome. The Mouse Genome Informatics
database (MGI, www.informatics.jax.org) refers to 562
Rosa26 knock-in mouse strains that have been generated
for probing the effects of constitutively or conditionally
expressed mutant proteins or for the imaging of reporter
genes in vivo. Rosa26 knock-in alleles are often configured
such that coding regions are expressed under the control
of the CAG hybrid promoter [5] or they are connected
with splice acceptor elements to the endogenous Rosa26
transcript [3]. Conditional gene expression is achieved by
insertion of a loxP-flanked transcriptional stop element
between the promoter and coding regions. In such a case,
gene expression is induced by crossing the conditional
knock-in line with transgenic mice expressing Cre recom-
binase in specific cell types [6].
Double-strand breaks (DSB) induced by engineered
nucleases in mouse zygotes have emerged as powerful
tool for the direct, single step production of targeted
mutants, independent of ES cells. Proof of principle was
provided with Zinc-finger nucleases and TALENs [7, 8],
both of which have been largely displaced by the more
versatile and efficient CRISPR/Cas9 gene editing system
[9]. This system is composed of the generic Cas9 nuclease
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that is guided to specific target sites by short sgRNAs
including 20 nucleotides complementary to the target
sequence upstream of a PAM signal (NGG). Gene
editing is achieved by endogenous DSB repair pathways,
either imprecisely by non-homologous end joining (NHEJ)
causing small deletions, or by homology-directed repair
(HDR) using repair template vectors for the precise inser-
tion of new sequences. In mouse zygotes, CRISPR/Cas9
has been efficiently used for generating small deletions
and knockout mutations by the NHEJ repair pathway,
reaching frequencies of 50 % in pups derived from RNA
microinjections [10, 11], even in inbred backgrounds such
as C57BL/6. In contrast, HDR events with co-injected tar-
geting vectors occur rarely in zygotes. A limited number
of studies reported the generation of knock-in alleles at
frequencies of 5–15 % for a small number of genes
[11, 12], not targeting Rosa26 and using genetic hybrid
embryos known for superior viability. Thus, an approach
for the direct production of Rosa26 knock-in alleles in
C57BL/6 embryos is presently not established, despite this
inbred background being a standard in biomedical
research.
Here we applied CRISPR/Cas9 for the knock-in of
conditional transgenes into Rosa26 of C57BL/6 zygotes.
Using modified Cas9 mRNA and sgRNA targeting the
intronic XbaI site of Rosa26, compatible with common
targeting vector homology regions, we achieved the
knock-in of 8–11 kb inserts in 10–20 % of pups derived
from microinjections of C57BL/6 embryos. This fre-
quency increased to 50 % upon the combined micro-
injection of Cas9 mRNA and Cas9 protein, as tested in
blastocyst assays. In addition to editing of the mouse
germ line in zygotes, CRISPR/Cas9 offers a new perspec-
tive for modifying gene function in somatic tissues. To
avoid the vector-mediated delivery of the large Cas9
transgene into primary cells, we generated Rosa26
knock-in mice for the Cre/loxP-dependent expression of
Cas9. Taken together, our protocols and resources sup-
port the fast and direct generation of new Rosa26
knock-in alleles and of Cas9-mediated in vivo gene edit-
ing in the C57BL/6 background.
Results
Efficient DSBs induction at the Rosa26 intronic XbaI site
in C57BL/6 zygotes
To achieve CRISPR/Cas9-mediated knock-in into Rosa26,
we selected sgRNA target sequences spanning the XbaI
site within the first intron, adapted to the homology
regions of gene targeting vectors used for ES cells that
cover sequences up- and downstream of this site [3]. As
we have shown previously, sgRosa26-1 (Fig. 1a) exhibits
high activity in mouse cells [13]. We therefore selected
sgRosa26-1, together with a Cas9 mRNA that includes a
plasmid coded polyadenine (polyA) tail (Cas9-162A) [14],
for targeting in zygotes. The most effective concentrations
of Cas9-162A and sgRosa26-1 RNAs were determined by
microinjection of varying amounts of RNA into the pro-
nuclei of C57BL/6 zygotes, followed by embryo culture to
the blastocyst stage. Genomic DNA was extracted from
each blastocyst and used for PCR amplification of the tar-
get region (Fig. 1b). PCR products were analyzed for NHEJ
repair-associated deletions by digestion with XbaI or the
T7 endonuclease I (T7EI). At the lowest concentrations of
Cas9-162A (5 ng/μl) and sgRosa26-1 (2.5 ng/μl) RNAs,
Rosa26 alleles from 40 % of the embryos exhibited se-
quence deletions, as shown by the presence of XbaI resist-
ant bands, whereas T7EI assays were less sensitive
(Fig. 1c). Sequencing of cloned PCR products from four
blastocysts confirmed the presence of small deletions at
the expected cleavage site. Of note, individual deletion
events could generate new XbaI sites, causing an under-
estimation of gene editing events by XbaI digestion
(Fig. 1d). Upon RNA microinjection of Cas9-162A at
25 ng/μl and sgRosa26-1 at 12.5 ng/μl, 80 % of cultured
embryos showed XbaI resistant PCR products, a percent-
age that was not further increased at higher concentra-
tions (Fig. 1e, Additional file 1: Figure S1). XbaI resistant
PCR products represented a minor fraction in most of the
samples, indicating the preferential modification of the
Rosa26 allele in a heterozygous and/or mosaic pattern, al-
though ~10 % of the embryos showed processing of both
alleles. We reasoned that conditions leading to Rosa26 de-
letions in the majority of embryos may also support
knock-in events in at least a fraction of embryos, since
HDR can occur in mammalian cells at ~10 % of nuclease
induced DSBs [15].
Knock-in of a conditional Cas9 transgene into Rosa26 of
C57BL/6 zygotes
To enable gene editing by CRISPR/Cas9 in vivo, we
aimed for germ line integration of a conditional Cas9
transgene into the Rosa26 locus of C57BL/6 mice such
that the delivery of the large Cas9 coding region into
primary cells can be avoided. As a template for HDR, we
constructed the targeting vector pRosa-Cas9, harboring
an 11 kb insert flanked by standard Rosa26 homology
regions, extending 1 kb upstream and 4 kb downstream
from the XbaI site mentioned above (Fig. 2a). The vector’s
insert includes a CAG promoter region, a loxP-flanked
transcriptional termination (Lox-Stop-Lox; LSL) element
and the Cas9 coding region linked to an IRES-GFP re-
porter element. In addition, splice acceptor and polyA ele-
ments were placed upstream of the CAG promoter for the
termination of the endogenous Rosa26 transcripts (Fig. 2a).
From pronuclear microinjections and transfer of 207
C57BL/6 zygotes with pRosa-Cas9 DNA, sgRosa26-1 and
Cas9-162A RNAs we obtained 38 live pups (Table 1). To
verify the activity of Cas9 in microinjected zygotes, these
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mice were first analyzed for the incidence of small dele-
tions at the Rosa26 target site. PCR amplification of the
target region on genomic DNA from ear biopsies using
the primer pair R26F2/R2 and the XbaI digestion assay
confirmed the presence of XbaI resistant, NHEJ processed
Rosa26 alleles in 28 of 38 pups (74 %) (Fig. 2b). Next, we
used a Cas9-specific primer pair for PCR and identified
six mice harboring the Cas9 transgene (Fig. 2c). These
potential founder mutants were further analysed to dis-
criminate knock-in alleles from random vector integra-
tions. None of these mice showed knock-in to both
Rosa26 alleles since additional wildtype or XbaI resist-
ant PCR products were detected using the R26F2/SAR/
R2 or F2/R2 primer combinations (Fig. 2c). For the
detection of correct, targeted integrations by PCR, we
used the R26F3 primer, recognizing a genomic sequence
outside of the upstream homology region of the targeting
vector, together with the vector specific primer SAR. The
predicted 1.38 kb PCR product could be amplified from
five of the six Cas9 transgenic mice, indicating the correct
configuration of the knock-in allele in founders #18, #20,
#35, #36 and #39 (Fig. 2d). Sequence analysis of these
PCR products confirmed their identity as being derived
from Rosa26LSL-Cas9 HDR alleles (Additional file 1: Figure
S2). In 4 of 5 founders, Southern blot analysis of EcoRI
digested tail DNA using a Rosa26-specific 5′-hybridization
probe showed the predicted 6.0 kb band and thus cor-
rectly targeted alleles, whereas founder #20 exhibited a
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Fig. 1 CRISPR/Cas9 induced DSBs at the Rosa26 intronic XbaI site in mouse zygotes. a: Diagram of the mouse Rosa26 locus. The sgRosa26-1 target
sequence upstream of the protospacer adjacent motif (PAM) and the XbaI site within the first intron are indicated. The locations of primers used
for nested PCR are shown (1. PCR: R26F1/R26R1, 2. PCR: R26F2/R26R2). b: In vitro blastocyst assay: zygotes microinjected with Cas9 mRNA and
sgRosa26-1 RNA were cultured for 4 days to blastocysts. Genomic DNA was extracted from each blastocyst and used for PCR amplification of the
target region and genotyping by XbaI or T7 endonuclease I (T7EI). c: Agarose gel electrophoresis of 0.2 kb PCR products amplified with the R26F2/
R26R2 primer pair from blastocysts derived from microinjected zygotes (25 ng/μl sgRosa26-1 and 50 ng/μl Cas9 mRNA) (top). PCR products were either
digested with XbaI (middle) or with T7EI (bottom). XbaI resistant 0.2 kb or T7EI sensitive 0.1 kb bands (arrows) indicate the presence of modified Rosa26
alleles harboring sequence deletions. WT – wildtype control, M – size marker. d: Sequence comparison of cloned PCR products (from c) amplified from
blastocysts #4 - #7 (from B). Deleted nucleotides are shown as dashes, the sgRosa26-1 PAM sequence is shown in red. e: Frequency of blastocysts
showing NHEJ-based mutagenesis as indicated by the presence of XbaI resistant Rosa26 PCR products, in relation to the concentrations of Cas9 and
sgRosa26-1 RNAs used for the microinjection of zygotes
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Fig. 2 Knock-in of a conditional Cas9 transgene into Rosa26 of C57BL/6 zygotes. a: Strategy for insertion of the CAG-loxPSTOPloxP-Cas9-IRES-EGFP
cassette into the mouse Rosa26 locus. sgRosa26-1 and Cas9 introduce a double-strand break between 1 kb and 4 kb fragments used as homology
arms in the targeting vector. Homology-directed repair (HDR) leads to the insertion of the cassette into the genome. The locations of PCR primers,
restriction sites and the Rosa26 hybridisation probe in the targeted and wildtype alleles are indicated. b: Gel electrophoresis of XbaI digested
Rosa26 PCR products (R26F2/R2 primers) amplified from pups (#7-#46) derived from microinjections of targeting vector, sgRosa26-1 and Cas9
RNAs. 0.2 kb bands of XbaI resistant products (mut) indicate sequence deletions, wildtype products (wt) are reduced to 0.1 kb. M - size marker,
B6 - C57BL/6 wildtype control. c: PCR detection of an internal segment of Cas9 in pups derived from microinjections using primers Cas9F/
Cas9R (top). Bottom: three primer PCR for the simultaneous detection of the Rosa26 target region (R26F2/R2 primers, 0.2 kb) and of vector
sequences (R26F2-SAR, 0.12 kb), showing that all samples harbor at least one nonrecombined Rosa26 allele. V – vector positive control, H2O –
negative control. d: Cas9-positive mice (from b) were further tested for correct knock-in (KI) into Rosa26 using a PCR reaction with a forward
primer located outside of the 5′-homology region (R26F3) and a reverse primer located in transgene (SAR); the predicted band has a size of
1.38 kb (top). Bottom: DNA quality was controlled with a Cas9 internal PCR (Cas9F/R primers,0.38 kb). H2O – negative control. e: Southern blot
analysis of EcoRI digested tail DNA from Cas9-positive mice (from b) using an external Rosa26-specific hybridization. Knock-in alleles are predicted to
show a 6 kb band. Control – DNA from a Rosa26 knock-in mouse generated from ES cells, C57BL/6 – wildtype control. f: Genotyping
PCR of 15 F1 pups derived from founder mutants #35 or #39 using the Cas9 internal primer pair Cas9F/R. g: Southern blot analysis of
EcoRI digested tail DNA from two F1 pups using an external Rosa26-specific hybridization probe. Control – DNA from a Rosa26 knock-in
mouse generated from ES cells, C57BL/6 – wildtype control
Table 1 Knock-in into the mouse Rosa26 locus using sgRNA and Cas9 mRNA
Donor vector Concentration (ng/μl) Injected zygotes Transferred embryos Live pups (%) Deletion alleles (%) Knock-in alleles (%)
Rosa26LSL-Cas9 10 105 60 7 (12) 3 (43) 0 (0)
20 183 147 31 (21) 25 (80) 5 (16)
Rosa26LSL-Lgals-Cd274 20 142 96 10 (10) ND 2 (20)
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larger band, in addition to the 15.6 kb fragment from the
Rosa26 wildtype locus (Fig. 2e). For germline transmission
of the targeted alleles, founders #18, 35, 36 and 39 were
crossed to C57BL/6 wildtype mice and their offspring
were genotyped using the Cas9 internal Cas9F/R primer
pair. All founders transmitted the Rosa26LSL-Cas9 allele to
about half of their offspring (Fig. 2f, Table 2). The Rosa26
loci of one pup each from founder #18 (#18-40) and #39
(#39-22) were further analyzed by Southern blotting of
EcoRI digested genomic DNA using an external Rosa26 5′
hybridization probe. Both pups showed the expected
6.0 kb band for the heterozygous Rosa26LSL-Cas9 allele, in
addition to the 15.6 kb band derived from the Rosa26
wildtype locus (Fig. 2g).
Thus, using Cas9 and sgRosa26-1 RNAs, we achieved
the targeted integration of an 11 kb conditional Cas9
transgene into the Rosa26 locus of C57BL/6 zygotes at a
frequency of 13 % and the Rosa26LSL-Cas9 founder
mutants transmitted the targeted allele through their
germ line.
Cas9 is functional in B cells of Rosa26LSL-Cas9 mice
To confirm the functionality of the Rosa26LSL-Cas9 allele,
we isolated naive B cells from spleens of three heterozy-
gous F1 mice by using CD43 microbeads because the
CD43 antigen is expressed on nearly all mouse leuko-
cytes except for immature and resting mature B cells.
The B cells were treated with cell permeable Tat-Cre
recombinase for deletion of the loxP-flanked stop
element, activated with LPS, inducing B cell prolifera-
tion and differentiation, for 2 days. The activated B
cells were harvested and used for isolation of genomic
DNA and cellular proteins (Fig. 3a). As shown by a
three primer PCR for the detection of the recombined
alleles, Tat-Cre removed the stop element with high
efficiency (Fig. 3b) and sequence analysis of the PCR
products confirmed the presence of a single loxP site
between the CAG promoter and the Cas9 coding re-
gion (Fig. 3c). The expression of Cas9 protein from
the activated Rosa26LSL-Cas9 allele was analyzed by
Western blotting using lysates of Tat-Cre treated B
cells and Cas9 or Flag-Tag specific antibodies. Both
antibodies verified the expression of the 156 kD Cas9
protein in Tat-Cre treated B cells from three hetero-
zygous Rosa26LSL-Cas9 mice (Fig. 3d).
The nuclease activity of the expressed Cas9 protein
was confirmed by the transduction of Tat-Cre treated,
LPS activated B cells with retroviral particles expressing
sgRosa26-1, a puromycin resistance and a BFP gene
(Fig. 4a). The transduced B cells of F1 Rosa26LSL-Cas9
heterozygous pups from three different founders (#18,
#35 and #39) were selected with puromycin for three
days, leading to an enrichment of BFP+ transduced cells
to 90 % (Fig. 4b). We then isolated genomic DNA from
FACS sorted BFP+ cells from the experimental and con-
trol cultures and performed PCR amplification of the
sgRosa26-1 target region, followed by XbaI digestion
and T7EI assays. In both groups, we found high levels of
XbaI resistant and T7E sensitive Rosa26 PCR products
(Fig. 4c), indicating sufficient Cas9 expression from the
conditional Rosa26LSL-Cas9 allele to achieve targeted
mutagenesis.
These results verified the expression of functional
Cas9 nuclease in Rosa26LSL-Cas9 F1 offspring upon Cre-
mediated activation of the transgene. Since the targeted
allele was introduced into C57BL/6 zygotes, the
Rosa26LSL-Cas9 mouse line allows Cas9-mediated gene
editing in vivo and in primary cells of C57BL/6 mice.
The Rosa26LSL-Cas9 line will be distributed through the
Jackson laboratory (www.jax.org).
Analysis of off-target activity
Genomic sequences showing high similarity to the
sgRosa26-1 target-sequence may lead to unintended
gene editing at such off-target sites. To determine the
importance of off-target modification in our system, we
predicted the off-target sites of sgRosa26-1 in the mouse
genome based on sequence similarity to its target-
sequence and selected the three sites with the highest
risk of being edited (Fig. 5a). We then amplified and se-
quenced these loci from six heterozygous Rosa26LSL-Cas9
F1-mice (derived from the founder mutants #18, #35 and
#39) and from the six Cas9 positive mice of the founder
generation (#18, #20, #35, #36, #39, #43). We did not de-
tect any genetic modification in all of the analysed off-
target loci, since solely wildtype, but no mixed sequence
reads were obtained (Fig. 5b-d, Additional file 1: Figure
S3). Although we cannot rule out off-target effects in
other loci, these results suggest that in the present set-
ting, off-target effects are not dominant.
Table 2 Germline transmission of Rosa26LSL-Cas9 alleles
Rosa26LSL-Cas9 founder # pups Male Female Rosa26LSL-Cas9 positive (%)
#18 (female) 9 7 2 5 (55)
#35 (male 15 8 7 10 (66)
#36 (male) 8 4 4 5 (47)
#39 (male) 17 8 9 7 (41)
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Knock-in of a conditional Galectin-1-E2A-PD-L1 transgene
into Rosa26 of C57BL/6 zygotes
Evidence that the Rosa26 targeting strategy outlined
above can be extended to other transgenes was obtained
in experiments aiming at the generation of signal-on al-
leles encoding the immunomodulatory proteins Galectin-
1 (Lgals1) and PD-L1 (Cd274), linked by a self-cleaving
E2A peptide. For this purpose we constructed a Rosa26
targeting vector by inserting the 8 kb transgene into a
Gateway cloning destination vector [16], harboring λ-
phage attR sites in between the loxP flanked stop element
and an IRES-GFP reporter gene (Fig. 6a). For knock-in
into the Rosa26 locus the Lgals1-E2A-Cd274 targeting
vector was microinjected together with sgRosa26-1
(12.5 ng/μl) and Cas9-162A (25 ng/μl) RNAs into the pro-
nuclei of 142 C57BL/6 zygotes. To control for embryo via-
bility, the injected zygotes were cultured overnight to the
2-cell stage. We recovered 96 such embryos (68 %) that,
upon transfer into foster mothers, resulted in the birth of
10 pups (Table 1). Genomic DNA from ear biopsies was
first used for the detection of vector integrations by PCR
amplification of an internal segment of the stop element
using the NeoF/R primer pair (Fig. 6b). Four pups showed
the predicted 324 bp band and were further genotyped
using the R26F3/SAR primer pair, enabling the detection
of Rosa26 HDR alleles by a forward primer (F3) outside of
the vector’s upstream homology region and a vector-
specific reverse primer (SAR). The predicted 1.38 kb PCR
product could be amplified from 2 pups (#90 and #95),
confirming the presence of Rosa26 knock-in alleles
(Fig. 6b). The presence of the protein coding segment was
further confirmed using an Lgals1 and Cd274 specific pri-
mer pair. In addition, we verified the correct integration
of the targeting vector in both founders by Southern blot
analysis of EcoRI digested tail DNA using an external
Rosa26 5′ hybridization probe. Both founders showed the
6.0 kb band predicted for the Rosa26Lgals-Cd274 allele, in
addition to the 15.6 kb band derived from the Rosa26
wildtype locus (Fig. 6b). The two founder mutants are
presently bred for germline transmission of the targeted
Rosa26LSL-Lgals/Cd274 allele.
In conclusion, the present direct targeting approach
using CRISPR/Cas9 in zygotes allows the rapid gener-
ation of new Rosa26 knock-in mouse lines on the
C57BL/6 inbred background. Since 10–17 % of trans-
ferred embryos developed into live pups and 10–20 % of
them were correctly targeted mutants, the establishment
of a new knock-in line requires the microinjection and
transfer of no more than 100–200 zygotes.
Resources for Rosa26 targeting in zygotes
To facilitate the construction of new conditional Rosa26
targeting vectors, we provide targeting vectors harboring
pairs of λ-attR sites for the insertion of coding regions in
between a loxP flanked stop element and an IRES-GFP
or -BFP reporter by Gateway cloning (Fig. 7). Each of
these versions either contains the CAG promoter for
transgene expression or an acceptor element for splicing
to the endogenous Rosa26 transcript. In addition, we
provide conditional targeting vectors enabling the
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Fig. 3 Cas9 is expressed in B cells of Rosa26LSL-Cas9 knock-in mice. a: Strategy for isolating naive B cells from spleens of three Rosa26LSL-Cas9 F1
mice by CD43 depletion and activation of Cas9 expression by deletion of the loxP flanked stop element upon treatment with TAT-Cre protein. b:
Scheme of the TAT-Cre-mediated deletion of the Neo/Stop element (left). Detection of Cre-mediated deletion of the Neo/STOP cassette by PCR
using DNA of TAT-Cre/LPS-treated B cells and the indicated primers. Rosa26LSL-Cas9 alleles produce a 1.0 kb band (CAGF-NeoR1 primers), Cre recombined
alleles are detected by a 0.7 kb band (CAGF/Cas9R1 primers). c: Sequencing results of 0.7 kb PCR products (from b) showing the correct deletion of the
loxP flanked stop element, leaving one loxP site in between the CAG promoter and the Cas9 coding region. d: Western blot analysis of lysates prepared
from TAT-Cre/LPS treated B cells of three Rosa26LSL-Cas9 F1 mice using antibodies against the Flag Tag, Cas9, or Beta-actin
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Fig. 4 Cas9 is functional in B cells of Rosa26LSL-Cas9 knock-in mice. a: Scheme of genome editing in primary mouse B cells using CRISPR/Cas9.
Naive B cells from spleens of three individual heterozygous Rosa26LSL-Cas9 F1 mice were isolated using CD43 depletion, treated with TAT-Cre and
stimulated with LPS for 24 h. TAT-Cre/LPS treated B cells were transduced with retroviral particles co-expressing sgRosa26-1 and BFP to target the
Rosa26 locus. One day later, the transduced B cells were selected with puromycin until day 5. b: FACS analysis of B cells (from a) before (day 2)
and after puromycin selection (day 5). The gate indicates the fraction (percentage) of successfully transduced BFP+ cells. c: Gel electrophoresis of
T7EI or XbaI digested PCR products (R26T7F/R26T7R primers) amplified from DNA of FACS sorted BFP+ cells (from b), indicating sequence deletions by
the presence of T7EI sensitive or XbaI resistant bands (arrows)
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Fig. 5 (See legend on next page.)
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standard cloning of new inserts into an AscI site located
upstream of an IRES-GFP reporter or into the AsiSI or
MluI site of a reporter-free plasmid (Fig. 7). For the
preparation of sgRosa26-1 and Cas9-162A RNAs for
microinjection we provide plasmids pBS-U6-sgRosa26-1
and pCAG-Cas9-162A. All plasmids will be distributed
via the Addgene repository (www.addgene.org) and pro-
tocols for RNA production and the PCR-based detection
of modified Rosa26 alleles and off-target analysis are in-
cluded in the Additional file 2.
In addition to the standard conditions with sgRosa26-
1 and Cas9-162A RNAs, as used for the generation of
Rosa26LSL-Cas9 and Rosa26LSL-Lgals/Cd274 mice, we ex-
plored whether the frequency of knock-in events can be
further increased by the co-injection of recombinant
Cas9 protein. For these test experiments we cultured
microinjected zygotes to the blastocyst stage, extracted
genomic DNA and determined the frequency of Rosa26
knock-in and deletion events by PCR. For the knock-in
into Rosa26, we used a Venus targeting vector harboring
the 1 kb standard 5′-homology region and a 3′-hom-
ology region shortened from 4 kb to 0.8 kb (Fig. 8a) to
facilitate the detection of recombined alleles by PCR
using the vector-specific primer VenusF and the external
downstream R26R3 primer (Table 3). We analyzed two
groups of 12 blastocysts each that were derived from the
microinjection of zygotes with aliquots of an identical
preparation of sgRosa26-1 RNA, Cas9-162A mRNA and
pRosa26-Venus DNA, except that one sample was sup-
plemented with Cas9 protein (30 ng/μl) immediately be-
fore injection. As shown in Fig. 8b, we found two
embryos (17 %) positive for the 1.38 kb knock-in PCR
product in the group microinjected with the RNA/DNA
preparation alone, comparable to our previous results.
In the group microinjected with additional Cas9 protein
6 of 12 embryos (50 %) were positive for the knock-in
PCR product. Although the small sample size prevents
statistical evaluation, it is possible that the combined use
(See figure on previous page.)
Fig. 5 Analysis of off-target activity. a: The top 18 predicted off-target sites of the Rosa26-1 target sequence sorted according to sequence divergence
(upper panel) and the PCR scheme for the analysis of the top 3 off-targets (lower panel). Negligible mismatches are shown in grey. b: PCR amplification
of the off-target site 1 (Off1) from two F1 pups each derived from the mutant founders #18, #35 or #39 (upper panel) and sequencing results of the
respective bands (lower panel, Bl6-C57Bl/6 wildtype control). c: PCR amplification of the off-target site 2 (Off2) from two F1 pups each derived from
the mutant founders #18, #35 or #39 (upper panel) and sequencing results of the respective bands (lower panel, Bl6-C57Bl/6 wildtype control). d: PCR
amplification of the off-target site 3 (Off3) from two F1 pups each derived from the mutant founders #18, #35 or #39 (upper panel) and sequencing
results of the respective bands (lower panel, Bl6-C57Bl/6 wildtype control)
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Fig. 6 Knock-in of a conditional Galectin-1-E2A-PDL1 transgene into Rosa26 of C57BL/6 zygotes. a: Strategy for insertion of the CAG-loxPSTOPloxP-
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are indicated. b: Gel electrophoresis of PCR reactions from genomic DNA of ten pups derived from microinjections using primers NeoF/R
for detection of an internal vector segment (stop element, top). Second panel: Mouse DNAs were further tested for correct knock-in (KI)
into Rosa26 using a PCR with a forward primer located outside of the 5′-homology region (R26F3) and a reverse primer located in transgene (SAR); the
predicted band has a size of 1.38 kb. Third panel: DNA quality was controlled with a Rosa26-specific PCR (R26wtF/R primers, 0.2 kb). Lower panel: PCR
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external Rosa26-specific hybridization probe. Knock-in alleles are predicted to show a 6 kb EcoRI band; for sample #89 the tail biopsy yielded insufficient
gDNA. Control – DNA from a Rosa26 knock-in mouse generated from ES cells, C57BL/6 – wildtype control
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of Cas9 mRNA and protein leads to increased Cas9
cleavage and improved HDR. The frequency of small de-
letions at the Rosa26 target site, as assessed by XbaI di-
gestion of PCR products, was also clearly elevated in
embryos co-injected with Cas9 protein (Fig. 6b).
Discussion
Efficient gene editing in mouse zygotes using the
CRISPR/Cas9 system has been mainly reported for the
generation of knockout alleles by small sequence dele-
tions in genetically hybrid embryos. However, many re-
search applications require precisely targeted mutations
on the C57BL/6 inbred background. Specifically, tar-
geted insertions into the Rosa26 locus are frequently
used for the constitutive or conditional expression of
transgenes in a standardized single copy configuration.
Here we established a CRISPR/Cas9 based approach for
generating Rosa26 knock-in alleles in C57BL/6 zygotes.
We found that transgene inserts of 8 or 11 kb were tar-
geted to Rosa26 in 10–20 % of the mice derived from
microinjections of 100–200 C57BL/6 zygotes. For the
detection of potential off-target modifications by Cas9,
we tested six Rosa26LSL-Cas9 F1 pups each at three pre-
dicted off-target sites. Since these sites showed no modi-
fications, we conclude that sgRosa26-1 does not lead to
obvious, frequent off-target processing.
To facilitate the future production of Rosa26 knock-in
mouse lines, we provide various targeting constructs
for the insertion of new transgenes using Gateway or
restriction site cloning. Furthermore, we found a higher
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proportion of Rosa26 knock-in alleles in a small group of
embryos microinjected with Cas9 mRNA and additional
Cas9 protein. Although this result is out of reliable statis-
tical evaluation, it is possible that the microinjection of
Cas9 protein and sgRNA stimulates DSB formation and
HDR early on, complementing and preceding the transla-
tion of Cas9 mRNA that supports sustained nuclease ac-
tivity over time. Thus, provided that live mutants will be
obtained at similar rates, the combined supply of Cas9
mRNA and protein could further streamline the produc-
tion of Rosa26 and other knock-in mutants, provided that
future experiments will confirm our initial findings. In
addition, the suppression of NHEJ repair by inhibition of
DNA Ligase IV [13, 17] may provide another option to in-
crease the yield of Rosa26 HDR alleles in zygotes. Since
we also successfully used a shortened, 0.8 kb 3′-homology
region for the knock-in of Venus into Rosa26, it will be in-
teresting to further investigate which lengths of homology
regions, in relation to the size of transgene inserts, are re-
quired for optimal HDR efficiency.
Previous studies on the direct targeting of Rosa26 used
pairs of zinc-finger nucleases [7] or TALEN [18] in zy-
gotes and achieved HDR frequencies of 1.7–4.5 % (ZFN)
or 5.8–11.7 % (TALEN), respectively, for the insertion of
reporter genes. Intrinsic limitations for DSB induction
by these earlier nuclease designs may be posed by the
requirement for binding of two protein molecules to the
target DNA and for the dimerization of their nuclease
domains. Since for Cas9, DSBs are formed by only one
single protein/RNA complex we reason that higher
levels of mutagenesis can be achieved by the delivery of
preformed Cas9/sgRNA into zygotes. As an alternative
to sequence-specific nucleases, Cre/loxP mediated recom-
bination has been used in zygotes for vector integrations
by recombinase-mediated cassette exchange (RMCE) into
a modified Rosa26 allele at efficiencies of 4.4–25 %
[19, 20]. However, the RMCE approach is incompat-
ible with the use of Cre/loxP dependent constructs
and requires the maintenance of a breeding colony of
RMCE acceptor mice for embryo production.
Using CRISPR/Cas9 we generated a new conditional
Cas9 mouse line for in vivo and ex vivo gene editing in
the C57BL/6 inbred background. A similar strain was
previously generated by gene targeting in 129-derived R1
ES cells [21]. A minimum of 10 backcross cycles with
C57BL/6 mice will be required for the establishment of
a congenic Cas9 strain, precluding prompt phenotypic
studies that require this widely used inbred background.
Since Rosa26 has been also validated as a ‘safe harbor’
integration site in rats and pigs using ES cells [22] or nu-
clear transfer [23], CRISPR/Cas9-based Rosa26 knock-in
in zygotes could also be of use in these species. Finally,
A B
C
Fig. 8 Coinjection of Cas9 mRNA and Cas9 protein into zygotes. a Strategy for insertion of a Venus reporter into the mouse Rosa26 locus.
sgRosa26-1 and Cas9 introduce a double-strand break between 1 kb and 0.8 kb fragments used as homology arms in the pR26-Venus targeting
vector. The locations of PCR primers in the targeted and wildtype Rosa26 alleles are indicated. SA- splice acceptor, pA polyadenylation site. b
Mouse zygotes were microinjected with pR26-Venus, sgRosa26-1 and Cas9 mRNA or Cas9 mRNA and protein. The embryos were cultured for
4 days and genomic DNA was isolated from 12 blastocysts each, for PCR-based detection of HDR or deletion events. Top panel: gel electrophoresis of
PCR products. Targeted alleles (KI) are detected by amplification of a 1.3 kb genomic segment using the vector-specific primer VenusF and the R26R3
primer, located downstream of the vector homology region. The presence of integrated or nonintegrated vector DNA was tested using the R26F2/R2
primer pair, amplifying a 1.4 kb vector segment as well as 0.2 kb of the Rosa26 target region (middle panel). Lower panel: Rosa26 alleles with sequence
deletions were detected by 0.2 kb of the target region (R26F2/R26R2 primers), followed by XbaI digestion and gel separation. XbaI resistant
PCR products indicate the presence of sequence deletions (mut, 0.2 kb) whereas wildtype products are reduced to 0.12 kb fragments (wt). c
Sequencing of PCR products amplified with primers VenusF and R26R3 (from B, top) showed the predicted recombination between the targeting
vectors homology region and adjacent downstream genomic sequence
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efficient targeting of the Rosa26 locus in the C57BL/6
background allows the direct targeting of complex ex-
perimental compound mutants and thus bypassing time-
consuming breeding strategies.
Conclusions
Rosa26 is frequently used as standardized insertion site
for single transgene copies via gene targeting in ES cells,
an approach that requires laborious handling of cell cul-
tures and 9–12 months’ time until the identification of
positive F1 pups. Here we applied CRISPR/Cas9-assisted
mutagenesis for the single step insertion of conditional
transgenes into Rosa26 of C57BL/6 zygotes. Using modi-
fied Cas9 mRNA and sgRNA targeting the intronic XbaI
site of Rosa26, we achieved the knock-in of 8–11 kb
inserts in 10–20 % of pups derived from microinjec-
tions of C57BL/6 embryos. Upon the combined
microinjection of Cas9 mRNA and Cas9 protein we
found knock-in alleles in 50 % of cultured blastocysts.
For modifying gene function by CRISPR/Cas9 in som-
atic tissues of C57BL/6 mice, to avoid the vector-
mediated delivery of the large Cas9 transgene into
primary cells, we generated Rosa26 knock-in mice for
the Cre/loxP-dependent expression of Cas9. Taken to-
gether, our protocols and resources support the fast
and direct generation of new Rosa26 knock-in alleles
and of Cas9-mediated in vivo gene editing in the
widely used C57BL/6 inbred strain.
Methods
Cloning of targeting vectors
Targeting vectors were cloned by modifying a published
Rosa26 targeting vector containing a loxP-flanked STOP
cassette and an IRES-GFP reporter [24]. A CAG pro-
moter, preceded by two copies of the bovine growth
hormone gene poly(A)-addition signal, was inserted
upstream of the STOP cassette using a PacI site as
previously published [25]. A diphtheria toxin gene
downstream of the 3′ homology arm was removed
using AgeI and AsisI restriction sites. cDNA coding
for Cas9 was amplified from plasmid pX330 (Addgene
#42230) and was inserted into the targeting vector
using an AscI restriction site. Lgals1 cDNA was amp-
lified from sequence NM_008495.2, Cd274 cDNA was
amplified from sequence NM_021893.3 (both from
plasmids provided by the DNA Resource Core at Harvard
Medical School) and the published sequence coding for
E2A was purchased as DNA oligonucleotides [26]. Lgals1-
E2A-Cd274 was assembled by overlapping PCR and
cloned into a Gateway entry vector using the pENTR/D-
TOPO Cloning Kit (Invitrogen). To convert the Rosa26
targeting vector into a destination plasmid, the AscI re-
striction site was used to insert a destination cassette
for Gateway cloning with the Gateway Vector Conver-
sion System (Invitrogen). Lgals1-E2A-Cd274 cDNA was
then transferred into the destination cassette of the tar-
geting vector using Gateway LR Clonase Enzyme Mix
(Invitrogen).
Microinjection of zygotes
Cas9 mRNA was prepared in a single step by in vitro
transcription from plasmid pCAG-Cas9-162A [14] line-
arized with AsiSI, AscI and XbaI using the mMessage
mMachine T7 Ultra kit (Life Technologies, Ambion,
AM1345, Life Technologies, Carlsbad, USA) (omitting
the polyadenylation step) and the MEGAclear kit
(Ambion, #1908). To produce the template for sgRNA
in vitro transcription, sgRosa26-1 was amplified by PCR
Table 3 PCR primers used in this study
PCR type Primer Sequence (5′ > 3′)
Nested PCR for
Rosa26 locus
R26F1 CCAAAGTCGCTCTGAGTTGTTATCAGT
R26R1 GGAGCGGGAGAAATGGATATGAAG
R26F2 GCCTCCTGGCTTCTGAGGACCG
R26R2 TCTGTGGGAAGTCTTGTCCCTCC
Cas9 transgene Cas9F GGCATCCTGCAGACAGTGAAGGTGG
Cas9R CGGTTCTTGTCGCTTCTGGTCAGCA
Homozygous
Heterozygous for
R26-Cas9 allele
R26F2 GCCTCCTGGCTTCTGAGGACCG
R26R2 TCTGTGGGAAGTCTTGTCCCTCC
SAR CCTGGACTACTGCGCCCTACAGA
Long PCR for correct
Integration R26F3 CTGCCCGAGCGGAAACGCCACTGAC
SAR CCTGGACTACTGCGCCCTACAGA
Neo transgene NeoF GCTAACCATGTTCATGCCTTC
NeoR CGTTGGCTACCCGTGATATT
Loading PCR for
Rosa26 locus
R26wtF GGAGTGTTGCAATACCTTTCTGGGAGTTC
R26wtR TGTCCCTCCAATTTTACACCTGTTCAATTC
Lgals-Cd274
transgene
Lgals1F CAAGATTAAGTGCGTGGCC
Cd274R CATTTCCCTTCAAAAGCTGGTC
Venus correct
integration
VenusF GGCCTCTCGAGCCTCTAGAACTATAGTG
R26R3 CAAGCTCACAAGACCTTAGGTCAGGA
LoxP-flanked Stop
cassette deletion
CagF CAAGCTCACAAGACCTTAGGTCAGGA
NeoR1 ATGGGATCGGCCATTGAACAAGATGG
Cas9R1 CGGCCTTGTCGGTGCTGTCCACCAG
PCR Rosa26 for T7EI
and RLFP
R26T7F CGTGCAAGTTGAGTCCATCCGCC
R26T7R ACTCCGAGGCGGATCACAAGCA
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from plasmid pX330-sgRosa26-1-T2A-BFP (Addgene
#64216) [13] with the forward primer T7-sgRosa26-for
(5′-TTAATACGACTCACTATAGGACTCCAGTCTTT
CTAGAAGAGT) and the reverse primer T7-sgRNArev
(5′-AAAAGCACCGACTCGGTGCC). One microgram
template DNA was used for in vitro transcription using
the Megashortscript kit (Ambion, #AM1354) followed by
the MEGAclear kit for RNA purification. The quality of
mRNAs was controlled by agarose gel electrophoresis
under denaturing conditions using the NorthernMax-Gly
system and the RNA Millenium size marker (Life Tech-
nologies). RNAs and targeting vectors were diluted in
microinjection buffer (10 mM Tris, 0.1 mM EDTA,
pH 7.2) to the indicated working concentrations, filtrated
through a centrifugal filter (Ultrafree, PFTE, Millipore,
cat. no. UFC30LG25) and stored in single use aliquots
at −80 °C. Where indicated, Cas9 protein (ToolGen
Inc, Seoul, South Corea) was supplemented immediately
before injection. Step-by-step protocols for RNA and sam-
ple preparation are included as Supplementary Methods
in the Additional file 2.
For microinjections, zygotes were obtained by mating
of C57BL/6 N males with super-ovulated C57BL/6 N fe-
males (Charles River, Sulzbach, Germany) using standard
procedures [27]. Zygotes were microinjected into one
pronucleus as previously described [28]. Injected zygotes
were transferred into the oviducts of pseudo-pregnant
NMRI female mice to obtain live pups. All mice showed
normal development and appeared healthy. Mice were
handled according to institutional guidelines and all
experiments were performed under registration and
ethical approvement (Registration No. IC10b-G0162/
12) by the Landesamt für Gesundheit and Soziales of
the federal state of Berlin (Turmstr. 21, 10559 Berlin,
Germany) Mice were housed in individually ventilated
cages (IVC, Tecniplast) in a specific pathogen-free facility
on a 12 h light/dark cycle with ad libitum access to food
and water.
PCR, T7EI and RLFP assays
Genomic DNA from blastocysts was extracted using the
QuickExtract DNA extraction kit (Epicentre) following
the manufacturer’s instructions. PCR was performed
using Herculase II Fusion DNA Polymerase (Agilent
Technology) with gene-specific primers. For the T7EI
assay, the PCR product was cleaned up and digested
with T7EI (New England Biolabs following the manufac-
turer’s instructions. For the RLFP assay, PCR products
were digested with the restriction enzyme XbaI (Thermo
Scientific). Cleaved DNA fragments were separated on
2 % agarose gels and the DNA concentration of each band
was quantified using the ImageJ software. Percent values
of indels were calculated as described [29]. For genotyping
by PCR, serial primer pairs were used as listed below.
DNA sequencing
Specific PCR products were cleaned up and directly se-
quenced by the Sanger method (LGCgenomics, Berlin,
Germany). In addition, the DNA fragments were cloned
into pSTblue-1 Blunt vector (Novagen), plasmids were
isolated using the NucleoSpin Plasmid kit (Macherey-
Nagel). Plasmids were sequenced using T7 forward primer.
Analysis of off-target sites
The Rosa26-protospacer (ACTCCAGTCTTTCTAGAA
GATGG) was aligned to the mouse genome (mm9)
using BWA (0.7.12) [30]. Off-target sites were evaluated
using an in-house developed tool for protospacer-design.
The primers used for PCR-ampflication were P1 (5′-
TTGGTTCCCAACACTCACAG-3′), R1 (5′-TGTGTAA
CTGCTCTGTTGTCTCC-3′), P2 (5′-CTTTGGGTTC
CCTCAGTAGAAG-3′), R2 (5′-AAGACCCAAACAGG
TATGCAG-3′), P3 (5′-CCACAGGGATAGGCAATA
AAGA-3′) and R3 (5′-GCTGAGCTGTCCCAATGA
GT-3′). PCR products were sequenced by the Sanger
method (LGCgenomics, Berlin, Germany) using R1, P2
and R3 for Off1, Off2 and Off3, respectively.
Southern blotting
Southern blotting for correct integration of the targeting
construct into the Rosa26 locus was done as described
[24]. Briefly, genomic DNA was isolated from tails and
10 μg were digested with EcoRI. DNA fragments were
separated on a 0.7 % agarose gel. The gel was washed
two times for 5 min in dH2O, incubated two times for
15 min in 0.125 M HCl for depurination, washed two
times for 5 min in H2O, and was finally denatured by in-
cubating two times for 15 min in 0.5 M NaOH/1.5 M
NaCl. DNA was blotted over night to a Hybond XL
membrane (GE Healthcare). The membrane was then
neutralized for 10 min in 0.5 M Tris–HCl pH 7.2/1 M
NaCl, dried, and UV-crosslinked by irradiation with
120,000 μJ cm−2. Then, the membrane was pre-
incubated for 3 h at 65 °C in ExpressHyb Hybridization
Solution (Takara). 25 ng probe was radioactively labeled
using Ladderman Labeling Kit (Takara) by adding
25 μCi 32P-dCTP and purified on a Sephadex-G50 col-
umn (GE Healthcare). The probe was first denatured
and then incubated with the membrane over night at
65 °C. Next, the membrane was briefly washed twice in
2 × SSC/1 % SDS, then incubated in 2 × SSC / 1 % SDS
for 30 min, then incubated in 1 × SSC / 1 % SDS for
30 min, followed by 0.5 × SSC / 1 % SDS for 30 min, all
at 65 °C. The membrane was used to expose an X-ray
film at −80 °C in the dark for 3 to 7 days.
B cell culture, stimulation and TAT-Cre treatment
Naïve B cells from Rosa26LSL-Cas9 and C57BL/6 mice
were isolated by CD43 depletion using CD43 microbeads
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(Miltenyi Biotec). B cells were cultured at 1x106 cells/ml
in DMEM medium supplied with 15 % FBS, 2 mM
HEPES (Gibco), 2 mM Sodium Pyruvate (Gibco),
2 mM L-Glutamine (Gibco), and 1x NAA (Gibco), beta-
mercapthoethanol (Sigma) and stimulated with LPS
(10 μg/ml). In addition, 5–10x106 naïve B cells isolated
from Rosa26LSL-Cas9 mice were treated with TAT-Cre
protein as previously described [31]. Briefly, CD43-
depleted B cells were washed 3 times with HyClone™
ADCF-Mab medium (GE Heathcare), incubated with
TAT-Cre for 45 min at 37 °C, finally the cells were
washed with complete medium. TAT-Cre-treated B cells
were stimulated with LPS for 2 or 3 days.
Retroviral transduction
The MSCV plasmid expressing the sgRNA to target the
mouse Rosa26 locus was transfected into the packaging
cell line Plat-E (Cell Biolabs) using Calcium phosphate
protocol. 24 h after transfection, the medium was chan-
ged and the transfected cells were incubated at 32 °C.
The viral supernatant was collected at 48 and 72 h after
transfection. The supernatant was concentrated using
Amicon Ultra-15 Centrifugal Filter (Merck) according to
the manufacture’s protocol. 5 × 105 of LPS-activated B
cells were transduced with concentrated retroviral parti-
cles using spin transduction method. The reporter posi-
tive cells were quantified using a Fortessa cell analyzer
(Becton Dickinson).
FACS sorting and analysis
The BFP+ B cells were sorted into 15 ml Falcon tubes
with complete medium, cells were centrifuged and gen-
omic DNA was isolated. For flow cytometry analysis, B
cells were harvested, washed 2x with cold PBS, resus-
pended in PBS/1 % BSA FACS buffer and stained with
anti-mouse CD19 Brilliant Violet 605™ and B220 Brilliant
Violet 785™ (Biolegend). The stained cells were analysed
with a Fortessa cell analyzer (Becton Dickinson). Dead
cells were excluded by DAPI (Sigma).
Western blot analysis
Naive B cells were treated with TAT-Cre protein, and
stimulated with LPS (10 μg/ml) for 2 days. The protein
lysates were isolated from the activated B cells as pre-
viously described [13] and separated by SDS-PAGE.
Blots were probed with anti-Flag (M2, Sigma), anti-
Cas9 (Novus Biologicals) and anti-beta-actin (AC-74,
Sigma) antibodies. The probed blots were developed
with secondary anti-mouse IgG HRP (eBioscience)
and visualised using the ECL detection kit (GE
Healthcare).
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